Back to School: How biopharma can reboot drug development. Access exclusive analysis here

IR501: Will begin by the end of July enrollment in a 90-patient Phase II trial

The Immune Response Corp.

Read the full 43 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE